DEFA14A: TransCode Therapeutics Faces Nasdaq Delisting Risk, Seeks Reverse Stock Split Authorization

TransCode Therapeutics is seeking shareholder authorization for a reverse stock split to maintain its Nasdaq listing after failing to meet the minimum bid requirement.

Summary

• TransCode Therapeutics has received notification from Nasdaq that its shares may be delisted because the common stock did not close at $1.00 per share or more for any ten day period ended May 6.
• The company intends to appeal this decision at a Nasdaq Panel Hearing.
• TransCode is requesting shareholder authorization for a reverse stock split as a measure to present to the Nasdaq Panel.
• The company believes that remaining listed on the Nasdaq Capital Market is valuable for future opportunities.
• The Annual Meeting is scheduled for June 13.
• The company's stock has closed above $1.00 per share for four consecutive days through May 10.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative due to the risk of delisting, but the company is taking proactive steps to address the issue. The management's tone suggests concern but also a determination to maintain the Nasdaq listing.

Positives

• TransCode intends to appeal the Nasdaq's delisting recommendation.
• The company's stock has closed above $1.00 per share for four consecutive days through May 10.
• The company is proactively seeking shareholder authorization for a reverse stock split to address the delisting risk.

Negatives

• TransCode's common stock did not meet the minimum bid requirement of $1.00 per share, leading to a delisting recommendation from Nasdaq.
• There is no guarantee that the reverse stock split authorization will prevent delisting.

Risks

• The company faces the risk of delisting from the Nasdaq Capital Market.
• The company's stock price may be negatively impacted if the reverse stock split is implemented.
• The company's ability to raise capital and pursue strategic opportunities may be hindered if it is delisted.

Future Outlook

The company hopes to avoid implementing a reverse stock split but believes it is necessary to seek authorization to maintain its Nasdaq listing.

Management Comments

• The Board of Directors and management do not wish to implement a reverse stock split and hope it will not be necessary.
• Management believes that maintaining a Nasdaq listing is in the best interest of shareholders.
• The company and its advisors believe that having shareholder authorization for a reverse split is the best chance to avoid delisting.

Industry Context

Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance, especially during periods of market volatility or when clinical trial results are delayed or disappointing. Reverse stock splits are a common tool used by these companies to regain compliance.

Comparison to Industry Standards

• Other biotech companies facing similar delisting risks, such as [Comparable Company A] and [Comparable Company B], have also considered or implemented reverse stock splits.
• The success of a reverse stock split in maintaining listing often depends on the company's ability to improve its financial performance and achieve key milestones, such as positive clinical trial results or regulatory approvals.

Stakeholder Impact

• Shareholders face the risk of dilution if a reverse stock split is implemented.
• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may be affected by potential cost-cutting measures or restructuring if the company faces financial difficulties.

Next Steps

• File a request for a Nasdaq Panel Hearing to appeal the delisting decision.
• Seek shareholder authorization for a reverse stock split at the Annual Meeting on June 13.
• Present arguments to the Nasdaq Panel to demonstrate the company's plan to regain compliance.

Key Dates

Keywords

reverse stock split, Nasdaq delisting, minimum bid requirement, RNAZ, TransCode Therapeutics, shareholder authorization